Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 4:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Follow up Clear all
Terminated Phase 2 Interventional Results available

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01846624
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults, AML (Adult) With 11q23 (MLL) Abnormalities, AML (Adult) With Del (5q), AML (Adult) With Inv (16) (p13; q22), AML (Adult) With t (16;16) (p13; q22), AML (Adult) With t (8; 21) (q22; q22), Secondary AML (Adult), Untreated AML (Adult)
Interventions
Decitabine, Midostaurin
Drug
Lead sponsor
David Iberri
Other
Eligibility
60 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Sep 13, 2026, 4:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

NCT02210559
View directory record Official record
Conditions
Pancreatic Cancer (Unresectable)
Interventions
FG-3019, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 13, 2026, 4:49 PM EDT
Completed Phase 2Phase 3 Interventional

RECONsolidation of Traumatic Memories to ResOLve Post Traumatic Stress Disorder (RECONTROLPTSD)

NCT03827057
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
Reconsolidation of Traumatic Memories (RTM), Prolonged Exposure (PE)
Behavioral
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 13, 2026, 4:49 PM EDT
Active, not recruiting No phase listed Observational

A Data Collection Protocol to Evaluate the Real World Usage of the Orthofix AccelStim Device to Treat Fresh Metatarsal Fractures

NCT07286357
View directory record Official record
Conditions
Metatarsal Fracture
Interventions
AccelStim (LIPUS)
Device
Lead sponsor
Orthofix Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Evanston, Illinois • Mount Prospect, Illinois • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 13, 2026, 4:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hospitalized Smokers

NCT01305928
View directory record Official record
Conditions
Hospitalized Smokers
Interventions
Warm Hand-off, Fax
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,054 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2016 · Synced Sep 13, 2026, 4:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The National Standard for Normal Fetal Growth

NCT00912132
View directory record Official record
Conditions
Pregnancy, Fetal Growth
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
2,802 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
11
States / cities
Birmingham, Alabama • Fountain Valley, California • Long Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 13, 2026, 4:49 PM EDT
Terminated Not applicable Interventional

Remote Monitoring of the Diabetic Foot to Prevent Re-Ulceration

NCT06053047
View directory record Official record
Conditions
Diabetic Foot
Interventions
Bluedrop Monitoring Service (BMS)
Device
Lead sponsor
Bluedrop Medical Limited
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 13, 2026, 4:49 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation

NCT05162638
View directory record Official record
Conditions
Multiple Sclerosis, Healthy
Interventions
thoracic duct cannulation
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 13, 2026, 4:49 PM EDT
Recruiting Phase 1 Interventional

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

NCT07201558
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Interventions
Surovatamig
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Birmingham, Alabama • Fullerton, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 13, 2026, 4:49 PM EDT
Not yet recruiting Not applicable Interventional

Facilitating Transition to Recommended PTSD Treatment

NCT05165940
View directory record Official record
Conditions
PTSD
Interventions
Treatment As Usual, New Health Services Intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 13, 2026, 4:49 PM EDT
Recruiting Phase 2 Interventional

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

NCT07191717
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma, Localized Estrogen Receptor-Positive Breast Carcinoma, Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma
Interventions
Abemaciclib, Biospecimen Collection, Imlunestrant, Questionnaire Administration, Radiologic Imaging Procedure
Drug · Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 13, 2026, 4:49 PM EDT
Recruiting Not applicable Interventional

REHAB Fontan Failure: A Trial of Cardiac Rehabilitation

NCT06150950
View directory record Official record
Conditions
Heart Failure Congenital, Single-ventricle
Interventions
Cardiac rehabilitation, Usual care
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Stanford, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 13, 2026, 4:49 PM EDT
Completed No phase listed Observational

Evaluating Patterned Oral Somatosensory Entrainment Stimulation Using the NTrainer on Oral Feeding Performance

NCT01069718
View directory record Official record
Conditions
Preterm Birth
Interventions
Not listed
Lead sponsor
KC BioMediX, Inc
Industry
Eligibility
34 Weeks to 18 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2010 · Synced Sep 13, 2026, 4:49 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

NCT02281084
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Oral Azacitidine, Durvalumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 13, 2026, 4:49 PM EDT
Completed No phase listed Observational

Long-term Follow-up of Spare the Nephron (STN) Patients

NCT01126333
View directory record Official record
Conditions
Kidney Transplant
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 13, 2026, 4:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Web-based Implementation for the Science of Enhancing Resilience Study

NCT02603133
View directory record Official record
Conditions
Burnout, Professional, Resilience, Psychological
Interventions
Three Good Things, Gratitude, Random Acts of Kindess, Awe, 1 Good Chat
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 85 Years
Enrollment
2,650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
9
States / cities
Palo Alto, California • Stanford, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 13, 2026, 4:49 PM EDT
Active, not recruiting Phase 1 Interventional

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

NCT03361852
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Rituximab, Neo Vax, Pembrolizumab
Drug · Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 13, 2026, 4:49 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall

NCT00826085
View directory record Official record
Conditions
Breast Cancer
Interventions
ThermoDox in combination with Microwave Hyperthermia (heat)
Drug
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
San Francisco, California • Newnan, Georgia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 13, 2026, 4:49 PM EDT
Active, not recruiting Not applicable Interventional

HOBSCOTCH for People With Post Acute COVID-19 Syndrome (PACS)

NCT06391489
View directory record Official record
Conditions
Post Acute COVID 19 Syndrome, Memory Impairment, Memory Dysfunction, Cognitive Dysfunction
Interventions
HOBSCOTCH-PACS
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
20 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 13, 2026, 4:49 PM EDT
Completed Phase 4 Interventional Results available

Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression

NCT00607789
View directory record Official record
Conditions
Binge Eating, Depression
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 13, 2026, 4:49 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

NCT03606174
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
Interventions
Sitravatinib, Nivolumab, Pembrolizumab, Enfortumab vedotin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
36
States / cities
Tucson, Arizona • Irvine, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 13, 2026, 4:49 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cognitive Control to Boost Physical Activity Adherence

NCT06338774
View directory record Official record
Conditions
Physical Inactivity
Interventions
Cognitive training, Exercise
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
40 Years to 65 Years
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Iowa City, Iowa • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 13, 2026, 4:49 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT

NCT00586274
View directory record Official record
Conditions
FANCONI ANEMIA
Interventions
CD34 selected haploidentical PBSCT, Fludarabine, T cell infusion, Campath 1h, anti-CD45
Procedure · Drug · Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 64 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 13, 2026, 4:49 PM EDT
Recruiting Not applicable Interventional

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

NCT04959474
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8, Breast Ductal Carcinoma in Situ, Invasive Breast Carcinoma, Triple Negative Breast Carcinoma
Interventions
Best Practice, Stereotactic Body Radiation Therapy, Resection, Sentinel Lymph Node Biopsy, Dietary Intervention, Questionnaire Administration, Quality-of-Life Assessment, Mammography, Biospecimen Collection
Other · Radiation · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 13, 2026, 4:49 PM EDT